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Introduction: Disparities in treatment exist for nonwhite and His-
panic patients with non-small cell lung cancer, but little is known
about disparities in the use of staging tests or their underlying
causes.
Methods: Prospective, observational cohort study of 3638 patients
with newly diagnosed non-small cell lung cancer from 4 large,
geographically defined regions, 5 integrated health care systems, and
13 VA health care facilities.
Results: Median age was 69 years, 62% were men, 26% were
Hispanic or nonwhite, 68% graduated high school, 50% had private
insurance, and 41% received care in the VA or another integrated
health care system. After adjustment, positron emission tomography
(PET) use was 13% lower among nonwhites and Hispanics than
non-Hispanic whites (risk ratio [RR] 0.87, 95% confidence interval
[CI] 0.77–0.97), 13% lower among those with Medicare than those
with private insurance (RR 0.87, 95% CI 0.76–0.99), and 24%
lower among those with an elementary school education than those
with a graduate degree (RR 0.76, 95% CI 0.57–0.98). Disparate use
of PET was not observed among patients who received care in an
integrated health care setting, but the association between race/
ethnicity and PET use was similar in magnitude across all other
subgroups. Further analysis showed that income, education, insur-
ance, and health care setting do not explain the association between
race/ethnicity and PET use.
Conclusions: Hispanics and nonwhites with non-small cell lung
cancer are less likely to receive PET imaging. This finding is
consistent across subgroups and not explained by differences in
income, education, or insurance coverage.
Key Words: Lung neoplasms, Carcinoma, Non-small cell lung,
Neoplasm staging, Tomography, Emission-computed, Healthcare
disparities.
(J Thorac Oncol. 2011;6: 875–883)
Accurate staging is crucial among patients with non-smallcell lung cancer (NSCLC), because both prognosis and
treatment selection are largely determined by disease stage.1,2
It is essential to accurately identify those individuals with
potentially resectable disease (stages I, II and sometimes
IIIA), in whom surgery remains the best option for cure. Most
patients with mediastinal lymph node involvement (stages
IIIA and IIIB) have limited options for cure, but concurrent
chemoradiation can prolong life and palliate symptoms.3 To
identify mediastinal metastasis, staging procedures include
imaging tests, such as computed tomography (CT) and pos-
itron emission tomography (PET), and a growing armamen-
tarium of invasive biopsy procedures.
PET is more accurate than CT for identifying malignant
mediastinal lymph nodes.4 Guidelines developed by the Amer-
ican College of Chest Physicians and the National Comprehen-
sive Cancer Network recommend that PET be used to help stage
lung cancer in patients who are candidates for curative treat-
ment.5,6 Three randomized controlled trials in patients with
potentially resectable NSCLC found that compared with con-
ventional staging, PET-based staging reduced the frequency of
thoracotomy without cure.7–9 However, in the majority of pa-
tients with NSCLC who have unresectable disease or are med-
ically inoperable, PET-based staging strategies have not been
evaluated in randomized trials. The use of imaging tests for
cancer staging is one of the Institute of Medicine’s top 25
priorities for comparative effectiveness research.10
Studies of disparities in lung cancer care have demon-
strated that African Americans and Hispanics are less likely
to receive potentially curative surgery,11–13 but the underlying
causes of these treatment disparities are incompletely under-
*VA Palo Alto Health Care System, Palo Alto, California; †Center for
Primary Care and Outcomes Research, Stanford University, Stanford,
California; ‡Keck School of Medicine, University of Southern Califor-
nia, Los Angeles, California; §VA Health Economics Research Center,
Menlo Park, California; Palo Alto Institute for Research and Education,
Palo Alto, California; ¶University of Iowa, Iowa City, Iowa; #Durham
Epidemiologic Research and Information Center, Durham VA Medical
Center, and Duke University, Durham, North Carolina; **Health Ser-
vices Research and Development Service, VA Puget Sound Health Care
System, and Department of Medicine, University of Washington, Seattle,
Washington.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Michael K. Gould, MD, MS, Keck School of
Medicine of USC, 2020 Zonal Avenue, IRD 715, Los Angeles, CA
90033. E-mail: mgould@usc.edu
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0605-0875
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 875
stood, and relatively little is known about disparities in
practices for lung cancer staging. One previous study found
that the frequency of multimodality staging (including PET)
was especially low among African Americans and persons
with low income or educational status.14 We sought to de-
scribe variation in PET use among patients with NSCLC;
identify sociodemographic and tumor characteristics associ-
ated with the use of PET; and examine whether income,
education, insurance, or health care setting modify or explain
disparate use of PET in members of racial and ethnic minority
groups.
PATIENTS AND METHODS
To examine the variation in PET use among patients
with NSCLC, we analyzed data collected by the Cancer Care
Outcomes Research and Surveillance (CanCORS) Consor-
tium, as part of a prospective observational study of cancer
care practices and outcomes for patients with lung and colo-
rectal cancer. The methods of the CanCORS “Share Thoughts
On Care” study have been reported previously in detail.15 The
CanCORS study, funded by the National Cancer Institute and
the VA Health Services Research and Development Service,
used data from medical records, patient interviews, and phy-
sician surveys to explore why some groups of cancer patients
are more likely than others to receive recommended treat-
ments and other interventions. For this analysis, we used
information found in version 1.8 of the CanCORS core data
files. All patients or an appropriate surrogate provided informed
consent. Human subjects committees at Stanford University and
all participating sites approved the study. See Supplemental
Digital Content (http://links.lww.com/JTO/A82) for additional
details about methods and results.
Patients
CanCORS used rapid case ascertainment to prospec-
tively enroll incident lung cancer cases in 4 large, geograph-
ically defined regions, 5 integrated health care delivery sys-
tems, and 13 health care facilities of the Veterans Health
Administration. Together, these settings capture approxi-
mately 10% of the total U.S. population and were responsible
for almost 10% of all U.S. lung cancer cases in 2000. Eligible
patients were diagnosed with lung cancer between September
1, 2003, and October 14, 2005. For this analysis, we included
all CanCORS participants with NSCLC who underwent med-
ical record abstraction.
Variables
Professional chart abstractors collected information
about variables of interest from the medical records of Can-
CORS participants, including patient characteristics (age,
gender, race, ethnicity, comorbidities, insurance, health care
setting), tumor characteristics (size, histology, stage), and use
of staging tests (CT, PET, bronchoscopy, mediastinoscopy,
endoscopic ultrasound). Collaborative stage was obtained
from chart abstraction or tumor registry. For a small propor-
tion of patients, the available stage was registry-classified as
local, regional, or distant. Therefore, in this analysis, we have
used those classifications, considering patients with stage I or
II as “local,” stage IIIa or IIIb as “regional,” and stage IV as
“distant.” In the base-case analysis, we considered PET to be
used for staging when the date of PET was known to be
before the date of first treatment. To summarize information
about comorbidities, the CanCORS study used the Adult
Comorbidity Evaluation-27 (ACE-27), a validated, medical
record-based instrument that ranks patients as having no,
mild, moderate, or severe comorbidity, according to the most
severe comorbid conditions identified.16,17 We obtained ad-
ditional information about annual household income and level
of education from the CanCORS baseline patient survey.
To allow for nonlinear effects and to simplify analysis
and interpretation, we dichotomized continuous variables (age
and tumor size) at the median value. Similarly, we transformed
CanCORS variables for race (17 categories) and ethnicity (7
categories) into a single variable with 3 categories (non-Hispanic
white, Hispanic or nonwhite, and unknown). We also trans-
formed CanCORS variables for primary and secondary insur-
ance (12 and 14 categories, respectively) by creating a single
variable in which patients were categorized as having private
insurance (if primary or secondary insurance was private), no
health insurance (if both primary and secondary were no insur-
ance), or nonprivate insurance (all others). We further subdi-
vided patients with nonprivate insurance as having Medicare (if
primary or secondary insurance was Medicare), Medicaid (if
primary insurance was Medicaid and secondary insurance was
not Medicare), or other nonprivate (all others with nonprivate
insurance). In addition, we created a variable to describe whether
the site of enrollment was a nonintegrated setting, an integrated
system (including Kaiser-Permanente members in Northern Cal-
ifornia and Los Angeles), or the VA Healthcare System. Finally,
we simplified the CanCORS histology variable (88 categories)
by placing each participant in one of four categories: adenocar-
cinoma, squamous cell carcinoma, other/mixed histology, or
NSCLC-not further specified. We recoded all variables before
data analysis.
Statistical Analysis
We report median, first quartile, and third quartile
values for continuous variables and counts and frequencies
for categorical variables. To perform between-groups com-
parisons of categorical variables, we used 2 tests. To identify
patient and tumor characteristics that were independently
associated with the use of PET, we performed multiple
logistic regression analyses that included all candidate pre-
dictor variables. In these analyses, we did not adjust for final
stage, because stage could be influenced by whether or not
PET was performed. Because use of PET was relatively
common, we report both odds ratios and approximate risk
ratios (RRs), which we estimated by using the method of
Zhang and Yu.18
We tested for clinically relevant subgroup effects by
entering all plausible interaction terms one at a time into the
full logistic model. We also repeated analyses after stratifying
by income, education, insurance coverage, and health care
setting. We developed additional logistic regression models
to examine whether one or more factors mediated (or ex-
plained) associations between race/ethnicity and use of PET,
including income, education, insurance, and health care set-
ting (Appendix Figure). When designing and interpreting
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these analyses, we used the definition of mediation proposed
by Baron and Kenny.19 Briefly, this definition of mediation
requires confirming the statistical significance of all of the
following: (a) an association between the exposure (e.g.,
race/ethnicity) and the potential mediator of interest (e.g.,
income), (b) an association between the exposure and the
outcome (e.g., use of PET), and (c) a difference in the beta
coefficients for the association between the exposure and the
outcome in models that did and did not include the mediator
of interest. To formally test the statistical significance of
mediator effects, we adapted the method of Preacher and
Hayes20 to generate mean Bootstrap estimates and their 95%
confidence limits for the difference between beta coefficients
for predictor variables in models that did and did not include
the mediator of interest.
Methods: Sensitivity Analysis
To test the robustness of our findings, we developed
additional logistic regression models that (a) excluded 782
patients who died within 3 months of diagnosis, (b) included
adjustment for disease stage, and (c) included patients in
whom the timing of PET relative to treatment was unknown
among those who were considered to have PET for staging.
RESULTS
Of 4550 potentially eligible CanCORS participants
with lung cancer, we excluded 153 patients who did not have
their medical records abstracted, 579 patients with small cell
carcinoma, and 180 patients with unknown tumor histology
(Figure 1). The resulting sample included 3638 CanCORS
participants with NSCLC, of whom 638 were enrolled at VA
sites.
Patient and Tumor Characteristics
The median age of the sample was 69 years (Table 1).
Almost two-thirds of participants were men, and 26% were of
Hispanic ethnicity or nonwhite race. Approximately half of
participants had moderate or severe comorbidities, 50% had
private health insurance, 34% had nonprivate insurance, and
1% had no insurance. Almost 70% graduated high school and
15% graduated from college. Annual household income was
less than $40,000 in 49%. The median tumor size was 40 mm.
Adenocarcinoma (35%) was more common than squamous
cell histology (24%). Stage distribution was nearly uniform,
although slightly fewer participants had stage III/regional
disease. Twenty-three percent of patients received care in an
integrated health care system and another 18% received care
in the Health Care System of the Department of Veterans
Affairs.
Staging Tests, Treatments, and Outcomes
More than 50% of CanCORS participants received PET
(Table 1), including 34% in whom the scan was performed
before treatment. The timing of PET relative to treatment was
unknown in another 13%. Only 5% underwent invasive
mediastinal staging (mediastinoscopy, endobronchial ultra-
FIGURE A1. Logistic regression models examining factors mediating associations between race/ethnicity and use of PET.
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sound, or endoscopic ultrasound). Just more than 50% under-
went bronchoscopy, but information about transbronchial
needle aspiration biopsy of mediastinal lymph nodes was not
recorded. Initial treatment included surgery in 33%, chemo-
therapy in 26%, radiation in 27% (including 5% who received
concurrent chemoradiation), and supportive care only in 19%
of participants. The median duration of follow-up from the
date of diagnosis was 270 days (interquartile range 83–254
days). Only 26% of the sample was alive at the time of last
contact.
Patient and Tumor Characteristics in Patients
Who Did and Did Not Receive PET
Compared with participants who did not receive PET
for staging, those who did were more likely to be younger,
non-Hispanic and white, and more highly educated (Table 2).
They were more likely to have private health insurance and
reported greater annual household income. PET recipients
were more likely to have local stage disease; undergo inva-
sive mediastinal staging; receive surgery, chemotherapy, or
radiation; and to survive until the end of follow-up.
In a multivariate analysis (Table 3), PET use was
approximately 9% lower in patients older than 69 years
(estimated RR 0.91, 95% CI 0.81–1.00), 13% lower in non-
whites and Hispanics (RR 0.87, 95% CI 0.77–0.97), and 17%
greater in patients with squamous cell carcinoma compared
with adenocarcinoma (RR 1.17, 95% CI 1.04–1.30). Com-
pared with patients with private health insurance, PET use
was similar among patients with Medicaid (RR 1.02, 95% CI
0.74–1.32), significantly lower among patients with Medi-
care (RR 0.87, 95% CI 0.76–0.99), and 30% lower among
those without health insurance (RR 0.70, 95% CI 0.39–1.12).
Compared with those with a graduate or professional degree,
PET use was less common among those who completed less
than 9 years of school (RR 0.76, 95% CI 0.57–0.98) and
those who attended but did not graduate from high school
(RR 0.80, 95% CI 0.61–1.01). Use of PET also increased
with increasing household income, but this association was
not statistically significant after adjusting for other variables.
Finally, compared with patients who received care in nonin-
tegrated health care settings, PET was used less frequently
among patients who received care in the VA (RR 0.76, 95%
CI 0.62–0.92) or an integrated health care system (RR 0.88,
95% CI 0.77–0.99).
Subgroup and Mediator Effects
In models that tested for subgroup effects, there were
no significant interactions between race/ethnicity and age
(p  0.99), gender (p  0.36), comorbidity (p  0.87),
insurance (p  0.32), income (p  0.42), education (p 
0.18), or health care setting (0.14). In stratified analyses,
nonwhites and Hispanics were less likely to receive PET
across all subgroups in analyses that were stratified by insur-
ance, income, or education. However, in an analysis stratified
by health care setting, PET was used less frequently among
nonwhites and Hispanics who received care in a noninte-
grated setting (RR 0.82, 95% CI 0.71–0.96) or VA facility
(RR 0.82, 95% CI 0.58–1.10) but not among those who
received care in an integrated system (RR 1.01, 95% CI
0.77–1.30). Further analysis revealed that while the fre-
quency of PET use differed widely across VA facilities (p 
0.0001), it was similar for whites and nonwhites after adjust-
ing for facility (p  0.84).
Compared with non-Hispanic whites, nonwhites and
Hispanics were approximately 23% less likely to have private
health insurance (RR 0.77, 95% CI 0.67–0.89), 19% less
likely to have graduated from high school (RR 0.81, 95% CI
0.70–0.92), 11% less likely to have an annual household
income greater than $60,000 (RR 0.89, 95% CI 0.72–1.07),
and 22% more likely to receive care in a nonintegrated setting
(RR 1.22, 95% CI 1.04–1.41). However, the less frequent use
of PET among nonwhites and Hispanics remained statisti-
cally significant and was unchanged in magnitude in analyses
that did and did not adjust for insurance status, income,
education, and health care setting (Supplemental Digital Con-
tent, http://links.lww.com/JTO/A82), indicating that these
factors did not explain the association between race/ethnicity
and PET use.
Sensitivity Analysis
Results were similar in an analysis that excluded 782
patients who did not survive for at least 3 months after
diagnosis, although education was no longer associated with
use of PET, whereas smaller tumor size (RR 0.84, 95% CI
0.75–0.93) and VA health care setting (RR 0.70, 95% CI
0.56–0.86) were more strongly associated with less frequent
PET use. Hispanics and nonwhites were even less likely to
receive PET when we modified our definition of PET use to
include patients in whom the timing of PET was uncertain
(RR 0.83, 95% CI 0.75–0.91), and when we controlled for
FIGURE 1. Cohort assembly. NSCLC, non-small cell lung
cancer; SCLC, small cell lung cancer.
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primary data collection and recruitment site, rather than
health care setting (RR 0.77, 95% CI 0.68–0.87) (Supple-
mental Digital Content, http://links.lww.com/JTO/A82).
In a multivariate analysis that also included final stage,
patients with local (RR 1.16, 95% CI 1.01–1.31) and regional
(RR 1.42, 95% CI 1.26–1.58) disease were both more likely to
receive PET, compared with those with distant disease (Supple-
mental Digital Content, http://links.lww.com/JTO/A82). Includ-
ing stage did not meaningfully change the magnitude or statis-
tical significance of the effect of any other variable.
In a model looking for differences across racial and
ethnic groups, PET use was less frequent among African
Americans (RR 0.83, 95% CI 0.70–0.97), Asians (RR 0.89,
0.67–1.14), and Hispanics (RR 0.87, 95% CI 0.66–1.12),
compared with non-Hispanic whites. Differences were
greater in magnitude and statistically significant for Asians
and Hispanics when our definition of PET use included
patients in whom the timing of PET was uncertain.
DISCUSSION
In this analysis of data from a large, prospective,
observational study of lung cancer practices and outcomes,
PET was used for diagnosis and/or staging in at least one-
third of all patients with NSCLC and probably used for these
indications in more than 50%. Compared with non-Hispanic
whites, PET was used approximately 13% less frequently
among nonwhites and Hispanics. Use of PET was also less
common among older patients, patients with Medicare or no
health insurance (compared with patients with private health
insurance), patients whose reported annual household income
was less than $20,000 (compared with higher income pa-
TABLE 1. Patient Characteristics, Tests, and Treatments
N (%)
Median age (IQR) 69 (61–76)
Male gender 2265 (62)
Race/ethnicity
White, non-Hispanic 2667 (73)
Hispanic ethnicity or nonwhite race 952 (26)
Hispanic or Latino 145
African American 463
Asian 140
Other 204
Unknown 19 (1)
Comorbidity
None 624 (17)
Mild 1329 (37)
Moderate 825 (23)
Severe 860 (24)
Insurance
Private 1810 (50)
Nonprivate 1231 (34)
Medicare 891
Medicaid 83
Other 257
None 40 (1)
Unknown 557 (15)
Highest education level
Elementary (K-8) 343 (9)
Some high school 396 (11)
High school graduate 1137 (31)
Some college or vocational school 812 (22)
College graduate 324 (9)
Graduate or professional degree 215 (6)
Unknown 411 (11)
Household income in U.S. dollars
20,000 955 (26)
20,000 to 40,000 847 (23)
40,000 to 60,000 425 (12)
60,000 435 (12)
Unknown 976 (27)
Median tumor size, mm (IQR) 40 (25–60)
Histology
Adenocarcinoma 1288 (35)
Squamous cell carcinoma 880 (24)
NSCLC 440 (12)
Final stagea
Local 1149 (32)
Regional 966 (27)
Distant 1329 (37)
Unknown 194 (5)
Health care setting
Nonintegrated setting 2167 (60)
Integrated health care system 833 (23)
VA Health Care System 638 (18)
Received CT 3126 (87)
(Continued)
TABLE 1. (Continued)
N (%)
Received PET 1858 (51)
Before diagnosis 369 (10)
Before treatment 856 (24)
After treatment 151 (4)
Timing not known 482 (13)
Received bronchoscopy 1810 (51)
Received mediastinal lymph node biopsy 190 (5)
Received initial treatmentb
Surgery 1188 (33)
Chemotherapy 950 (26)
Radiation 989 (27)
None 678 (19)
Received any treatmentb
Surgery 1282 (35)
Chemotherapy 1710 (47)
Radiation 1602 (44)
Alive at last follow-up 951 (26)
N  3638; values are presented as N (%), unless otherwise noted.
a Patients who received multimodality treatment are included in more than one
category.
b Patients with local (stage I or II), regional (stage III), or distant (stage IV) disease.
CT, computed tomography; IQR, interquartile range; PET, positron emission
tomography.
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tients), and patients who received care in the VA or another
integrated system. Not surprisingly, PET was used more
frequently in patients with local or regional disease and those
treated by surgery.
One novel aspect of our study is that we attempted to
identify subgroups in which the association between race/
ethnicity and use of PET was especially strong or weak. In
these analyses, we found that the association between race/
ethnicity and PET use was not significantly different in
subgroups defined by income, education, or insurance cover-
age. While we did not find a statistically significant interac-
tion between race/ethnicity and health care setting, stratified
analyses revealed that disparate use of PET was not observed
among patients who received care in an integrated health care
system, suggesting that access to PET may be more equitable
in these settings.
Another innovative aspect of our study is that we
adapted well-established methods from social science to iden-
tify factors that might explain why PET was used less
frequently in nonwhites and Hispanics. Somewhat surpris-
ingly, results of these analyses did not support the hypothesis
that differences in income, education, insurance coverage, or
health care setting explained the association between non-
white race/ethnicity and less frequent use of PET. Our results
suggest that not only race/ethnicity is an independent predic-
tor of PET use but also differences in income, education, and
insurance coverage are not responsible for the association
between race/ethnicity and PET use.
TABLE 2. Comparison of Patients Who Did and Did Not
Receive PET Before Treatment
PET No PET p
Age 69 yr 653 (53) 1202 (50) 0.05
Male sex 739 (60) 1526 (63) 0.09
Race/ethnicity 0.001
White, non-Hispanic 944 (77) 1723 (71)
Hispanic ethnicity or nonwhite
race
274 (22) 678 (28)
African American 125 338
Hispanic 42 103
Asian 43 97
Other 64 152
Unknown 7 (1) 12 (1)
Comorbidity 0.002
None 170 (14) 454 (19)
Mild 460 (38) 869 (36)
Moderate 301 (25) 524 (22)
Severe 294 (24) 566 (24)
Insurance 0.0001
Private 715 (58) 1095 (45)
Nonprivate 348 (28) 883 (37)
Medicare 252 639
Medicaid 29 54
Other 67 190
None 10 (1) 30 (1)
Unknown 152 (12) 405 (17)
Highest education level 0.007
Elementary (K-8) 98 (8) 245 (10)
Some high school 120 (10) 276 (11)
High school graduate 395 (32) 742 (31)
Some college or vocational
school
309 (25) 503 (21)
College graduate 122 (10) 202 (8)
Graduate or professional
degree
89 (8) 126 (5)
Household income in U.S. dollars 0.007
20,000 290 (24) 665 (28)
20,000 to 40,000 305 (25) 542 (23)
40,000 to 60,000 167 (14) 258 (11)
60,000 172 (14) 263 (11)
Unknown 291 (24) 685 (28)
Median tumor size 0.0001
40 mm 495 (40) 814 (34)
40 mm 532 (43) 831 (34)
Unknown 198 (16) 768 (32)
Histology 0.0001
Adenocarcinoma 450 (37) 838 (35)
Squamous cell carcinoma 326 (27) 554 (23)
NSCLC 103 (8) 337 (14)
Other/mixed 346 (28) 684 (28)
Final stage 0.0001
Local 427 (35) 722 (30)
Regional 390 (32) 576 (24)
Distant 370 (30) 959 (40)
Unknown 38 (3) 156 (7)
(Continued)
TABLE 2. (Continued)
PET No PET p
Health care setting 0.0001
Nonintegrated setting 802 (66) 1365 (57)
Integrated health care system 262 (21) 571 (24)
VA Health Care System 161 (13) 477 (20)
Received CT 1123 (92) 2003 (85) 0.0001
Received PET
Before diagnosis 369 (30) NA
Before treatment 856 (70) NA
Received bronchoscopy 681 (56) 1129 (48) 0.0001
Received mediastinal lymph node
biopsy
96 (8) 94 (4) 0.0001
Received initial treatment
Surgery 433 (35) 755 (31) 0.01
Chemotherapy 472 (39) 478 (20) 0.0001
Radiation 390 (32) 599 (25) 0.0001
None 37 (3) 641 (27) 0.0001
Received any treatment
Surgery 502 (41) 780 (32) 0.0001
Chemotherapy 761 (62) 949 (39) 0.0001
Radiation 665 (54) 937 (39) 0.0001
Alive at last follow-up 366 (30) 585 (24) 0.0003
Values are presented as N (%).
p values represent two-tailed 2 tests comparing the PET and no PET groups.
NSCLC, non-small cell lung cancer; CT, computed tomography; PET, positron
emission tomography.
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Other factors that might explain the lower frequency of
PET use among nonwhites and Hispanics include presenta-
tion with more advanced disease,21,22 limited access to imag-
ing centers and hospitals that have PET scanners, patient
preferences for less aggressive staging and treatment,23,24 and
conscious or unconscious biases of clinicians. Consistent
TABLE 3. Independent Predictors of PET Use
Characteristic
Underwent PET,
N (%)
Odds
Ratio
OR
95% CI
Relative
Risk
RR
95% CI p
Age (yr) 0.06
69 653 (35) 1.00 1.00
69 572 (32) 0.86 0.74–1.01 0.91 0.82–1.00
Gender 0.84
Male 739 (33) 1.00 1.00
Female 486 (35) 1.02 0.87–1.28 1.01 0.91–1.12
Race/ethnicity 0.02
Non-Hispanic white 944 (35) 1.00 1.00
Nonwhite/Hispanic 274 (29) 0.81 0.68–0.96 0.87 0.77–0.97
Unknown 7 (37) 1.77 0.65–4.79 1.39 0.74–2.06
Comorbidity 0.05
Severe 294 (34) 1.00 1.00
None 170 (27) 0.76 0.59–0.97 0.83 0.69–0.98
Mild 460 (35) 0.99 0.82–1.19 0.99 0.87–1.12
Moderate 301 (36) 1.06 0.86–1.31 1.04 0.90–1.18
Insurance 0.05
Private 715 (40) 1.00 1.00
Medicare 252 (28) 0.80 0.66–0.98 0.87 0.76–0.99
Medicaid 29 (35) 1.03 0.63–1.68 1.02 0.74–1.32
Other 67 (26) 0.85 0.59–1.23 0.91 0.71–1.26
None 10 (25) 0.58 0.28–1.23 0.70 0.39–1.12
Unknown 152 (27) 0.75 0.60–0.93 0.83 0.71–0.96
Highest education level 0.02
Graduate or professional degree 89 (41) 1.00 1.00
Elementary (K-8) 98 (29) 0.65 0.44–0.96 0.76 0.57–0.98
Some high school 120 (30) 0.70 0.48–1.01 0.80 0.61–1.01
High school graduate 395 (35) 0.83 0.60–1.14 0.89 0.72–1.08
Some college/vocational school 309 (38) 0.90 0.65–1.24 0.94 0.76–1.13
College graduate 122 (38) 0.91 0.63–1.31 0.94 0.74–1.16
Unknown 92 (22) 0.53 0.34–0.82 0.66 0.47–0.89
Annual household income ($) 0.26
60,000 172 (40) 1.00 1.00
20,000 290 (30) 0.80 0.61–1.05 0.87 0.72–1.03
20,000 to 40,000 305 (36) 0.95 0.73–1.24 0.97 0.82–1.13
40,000 to 60,000 167 (39) 1.05 0.79–1.40 1.03 0.86–1.21
Unknown 291 (30) 0.92 0.69–1.21 0.95 0.79–1.12
Median tumor size 0.0001
40 mm 532 (39) 1.00 1.00
40 mm 495 (38) 0.91 0.78–1.08 0.95 0.85–1.05
Unknown 198 (21) 0.44 0.36–0.54 0.56 0.48–0.66
Histology 0.001
Adenocarcinoma 450 (35) 1.00 1.00
Squamous cell 326 (37) 1.28 1.06–1.55 1.17 1.04–1.30
NSCLC 103 (23) 0.73 0.56–0.95 0.80 0.66–0.96
Other/mixed 346 (34) 1.11 0.93–1.33 1.07 0.95–1.19
Health care setting 0.004
Nonintegrated 802 (37) 1.00 1.00
Integrated 262 (31) 0.82 0.68–0.98 0.88 0.77–0.99
VA 161 (25) 0.67 0.50–0.88 0.76 0.62–0.92
PET, positron emission tomography; CI, confidence interval.
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with all of these possibilities, the association between race/
ethnicity and PET use was statistically significant and great-
est in magnitude among African Americans. However, our
finding that disparities in PET use were similar for African
Americans, Asians, and Hispanics makes it unlikely that a
single, specific language barrier and/or cultural factor is
responsible, as does our finding that disparities were not seen
among patients who received care in an integrated health care
system. We distinguished between integrated and noninte-
grated settings to test the hypothesis that the type of delivery
system is associated with the likelihood of PET use and found
that PET was used more frequently in nonintegrated settings,
suggesting that financial incentives may be an important
determinant of PET use “at the margin,” possibly including
both “overuse” in nonintegrated settings and “underuse” in
integrated systems.
Prior studies have shown that lung cancer surgery is
less common in African Americans,11,25 Hispanics,12 non-
elderly Medicare beneficiaries with disabilities,26 octogenar-
ians,27 and those with low incomes.25 Lathan et al.28 reported
that blacks with NSCLC were approximately 25% less likely
to undergo invasive staging, defined as receipt of bronchos-
copy, mediastinoscopy, or thoracoscopy. Similarly, Farjah et
al.14 found that only 1% of African Americans underwent
trimodality staging (CT, PET, and invasive biopsy), com-
pared with 3% of whites. They also found that overall rates of
bimodality staging (CT and PET or CT and invasive biopsy)
were 14% in African Americans and 21% in whites, a
difference that is somewhat greater (in relative terms) than
the 13% difference in PET use that we observed. Similar to
what we reported for PET use, they found a lower likelihood
of bimodality or trimodality staging among older patients and
those with income in the lowest quartile. More recently, Suga
et al.29 used data from the California Cancer Registry to
identify 12,395 patients who were diagnosed with NSCLC
between 1994 and 2004. In contrast to our results, they found
that nonwhites were no less likely than whites to receive PET.
However, our study included a greater percentage of African
Americans (12.7% versus 6.0%), and the overall frequency of
PET use was much greater (51% versus 14.6%), reflecting the
more recent data collection period. Of note, within-site dif-
ferences between whites and nonwhites in our study were
greater in magnitude for the two CanCORS regions in Cali-
fornia than any other data collection and recruitment site
(data not shown), suggesting the possibility that race and
ethnicity-based disparities in PET use in California have
become more severe over time as the technology has dissem-
inated more widely.
Strengths of our study include the large, prospectively
enrolled and geographically diverse sample, the collection of
detailed sociodemographic information with limited amounts
of missing data, and use of rigorous analytical methods.
Important limitations include the potential for residual con-
founding, although we adjusted for all available variables that
might be associated with both the exposure (race/ethnicity)
and the outcome (use of PET). In addition, because the
CanCORS study did not collect information about CT and
PET results, we were not able to report intermediate out-
comes such as upstaging and downstaging nor were we able
to determine rates of futile thoracotomy or changes in treat-
ment planning. Because assignment to PET was nonrandom
and differences in baseline characteristics persisted even after
adjustment by propensity score methods (data not shown), we
did not attempt to compare survival among patients who did
and did not receive PET.
Finally, our study was not designed to determine whether
PET was underutilized in nonwhites and Hispanics or over-
used in non-Hispanic whites. American College of Chest
Physicians guidelines recommend that PET be used to char-
acterize solitary pulmonary nodules (CT stage IA) when the
clinical probability of malignancy is low to moderate30 and
for noninvasive staging in patients with clinical (CT) stage IB
to IIIB NSCLC who are candidates for treatment with cura-
tive intent.6 In this study, we were not able to determine the
appropriateness of PET use because information about CT
stage was not available. While PET-based staging in NSCLC
has been shown to reduce the frequency of futile thoracot-
omy, it has not been shown to improve survival, and the
potential benefits of PET-based staging have not been dem-
onstrated in patients who are not candidates for surgical cure.
Future studies should attempt to identify subgroups of pa-
tients with NSCLC who are most likely to benefit from
staging that includes PET.
In summary, we found that PET imaging was com-
monly used for diagnosis and/or staging in patients with
NSCLC, but there was substantial variation in use. With the
exception of those who received care in an integrated health
care system, Hispanics and nonwhites with NSCLC were less
likely to receive PET. This finding was consistent across
subgroups and not explained by differences in income, edu-
cation, or insurance coverage. PET was also used less fre-
quently among older patients, and among those with Medi-
care or no health insurance and those with very low income,
suggesting that this technology is being differentially applied
for reasons unrelated to clinical status.
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